Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany

Gaby Sroczynski, Petra Schnell-Inderst, Nikolai Mühlberger, Katharina Lang, Pamela Aidelsburger, Jürgen Wasem, Thomas Mittendorf, Jutta Engel, Peter Hillemanns, Karl Ulrich Petry, Alexander Krämer & Uwe Siebert
Background Persistent infections with high-risk types of human papillomavirus (HPV) are associated with the development of cervical neoplasia. Compared to cytology HPV testing is more sensitive in detecting high-grade cervical cancer precursors, but with lower specificity. HPV based primary screening for cervical cancer is currently discussed in Germany. Decisions should be based on a systematic evaluation of the long-term effectiveness and cost-effectiveness of HPV based primary screening. Research questions What is the long-term clinical effectiveness...